Eribulin mesylate.

Nature reviews. Drug discovery ·Vol. 10 ·No. 3 ·2011-03-00 ·Pages 173-4

Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/adverse effects,pharmacology,therapeutic use Breast Neoplasms/drug therapy Drug Approval Ethers, Cyclic/chemistry,pharmacology Female Furans/adverse effects,pharmacology,therapeutic use Humans Ketones/adverse effects,pharmacology,therapeutic use Macrolides Mesylates/adverse effects,pharmacology,therapeutic use Microtubules/drug effects Neoplasm Metastasis

Chemicals

Antineoplastic Agents Ethers, Cyclic Furans Ketones Macrolides Mesylates halichondrin B eribulin

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Huyck Timothy K

Gradishar William

Manuguid Fil

Kirkpatrick Peter

References (12)

12 references, click to expand

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Clin Breast Cancer. 2010 Apr;10(2):160-3 PMID: 20299316
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.
Breast Cancer Res Treat. 2008 Jan;107(2):275-9 PMID: 17380382
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Cancer Res. 2004 Aug 15;64(16):5760-6 PMID: 15313917
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
J Clin Oncol. 2010 Sep 1;28(25):3922-8 PMID: 20679609
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Cancer Res. 2001 Feb 1;61(3):1013-21 PMID: 11221827
Microtubule-binding agents: a dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 2010 Oct;9(10):790-803 PMID: 20885410
The halichondrins and E7389.
Chem Rev. 2009 Jul;109(7):3044-79 PMID: 19534494
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.
Mol Pharmacol. 2006 Dec;70(6):1866-75 PMID: 16940412
Structurally simplified macrolactone analogues of halichondrin B.
Bioorg Med Chem Lett. 2004 Nov 15;14(22):5547-50 PMID: 15482921
Third consensus on medical treatment of metastatic breast cancer.
Ann Oncol. 2009 Nov;20(11):1771-85 PMID: 19608616
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
Mol Cancer Ther. 2005 Jul;4(7):1086-95 PMID: 16020666
Treatment options for breast cancer resistant to anthracycline and taxane.
Mayo Clin Proc. 2009 Jun;84(6):533-45 PMID: 19483170

Article Info

Journal

Nature reviews. Drug discovery

Abbr.

Nat Rev Drug Discov

ISSN

1474-1784

DOI

10.1038/nrd3389

Published

2011-03-00

Pages

173-4

Language

English

Region

England

NLM ID

101124171

Subset

External Links

PubMed source DOI: 10.1038/nrd3389 View journal details

Analysis Services

Eribulin mesylate.

Contact

WeChat Official Account